Hoth Therapeutics, Inc. 8-K

What Happened
Hoth Therapeutics, Inc. (Nasdaq: HOTH) filed an 8-K reporting that on April 30, 2026 Nasdaq notified the company it is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Based on closing bid prices from March 18, 2026 through April 29, 2026, Hoth’s shares failed to maintain the required $1.00 minimum. The notice does not affect current trading — HOTH will continue to trade on Nasdaq.

Key Details

• Nasdaq notified Hoth on April 30, 2026 that it failed the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)); deficiency determined under Nasdaq Rule 5810(c)(3)(A).
• Hoth has 180 calendar days (until October 27, 2026) to regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive business days.
• If not cured, Hoth may be eligible for an additional 180-day extension if it meets other Nasdaq continued listing requirements and submits a written plan to cure.
• The company said it will monitor the share price and may consider options such as a reverse stock split to regain compliance.

Why It Matters
This is a compliance matter that could lead to delisting if not resolved. Trading continues for now, but failure to regain the $1.00 bid price within the allowed cure periods could result in Nasdaq delisting proceedings — which can reduce liquidity and limit where the stock trades. Investors should watch the company’s share price, any shareholder actions (like a reverse split), and future company updates about a compliance plan.